Peanut allergy drug from Peninsula company approved by FDA
Aimmune Therapeutics Inc. ended a nearly nine-year quest Friday by winning Food and Drug Administration for a first-of-its-kind peanut allergy treatment that protects people from potentially lethal accidental exposures.
The oral immunotherapy, a capsule of powderized peanut protein called Palforzia, is approved for kids ages 4-17 — a group whose parents kickstarted the Brisbane company's founding in 2011 after a venting meeting with clinicians, advocacy groups, regulators and drug developers.
"They…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Allergy | Allergy & Immunology | Children | Food and Drug Administration (FDA) | Health Management | Immunotherapy | Peanuts | Pharmaceuticals